JP2011500583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500583A5 JP2011500583A5 JP2010529013A JP2010529013A JP2011500583A5 JP 2011500583 A5 JP2011500583 A5 JP 2011500583A5 JP 2010529013 A JP2010529013 A JP 2010529013A JP 2010529013 A JP2010529013 A JP 2010529013A JP 2011500583 A5 JP2011500583 A5 JP 2011500583A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture according
- excipient
- sodium
- hpmc
- silicon dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 238000000825 ultraviolet detection Methods 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- -1 Avicel PH101 Chemical compound 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YEDTWOLJNQYBPU-UHFFFAOYSA-N [Na].[Na].[Na] Chemical compound [Na].[Na].[Na] YEDTWOLJNQYBPU-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97948207P | 2007-10-12 | 2007-10-12 | |
| US60/979,482 | 2007-10-12 | ||
| PCT/US2008/079264 WO2009048993A2 (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246066A Division JP2015091822A (ja) | 2007-10-12 | 2014-12-04 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500583A JP2011500583A (ja) | 2011-01-06 |
| JP2011500583A5 true JP2011500583A5 (https=) | 2016-09-08 |
| JP6034000B2 JP6034000B2 (ja) | 2016-11-30 |
Family
ID=40032615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529013A Active JP6034000B2 (ja) | 2007-10-12 | 2008-10-09 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物 |
| JP2014246066A Pending JP2015091822A (ja) | 2007-10-12 | 2014-12-04 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246066A Pending JP2015091822A (ja) | 2007-10-12 | 2014-12-04 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物 |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8673918B2 (https=) |
| EP (7) | EP3733161A1 (https=) |
| JP (2) | JP6034000B2 (https=) |
| KR (3) | KR20170021904A (https=) |
| CN (1) | CN101820916A (https=) |
| AR (1) | AR068986A1 (https=) |
| AU (1) | AU2008310846C1 (https=) |
| BR (1) | BRPI0818161B8 (https=) |
| CA (2) | CA2699788C (https=) |
| CL (1) | CL2008003003A1 (https=) |
| CO (1) | CO6270342A2 (https=) |
| DK (1) | DK2952177T3 (https=) |
| EC (1) | ECSP10010169A (https=) |
| ES (2) | ES2545361T3 (https=) |
| HR (1) | HRP20150838T1 (https=) |
| HU (2) | HUE027696T2 (https=) |
| IL (3) | IL204514B (https=) |
| JO (2) | JOP20080436B1 (https=) |
| MA (1) | MA31799B1 (https=) |
| MX (1) | MX337152B (https=) |
| MY (1) | MY159358A (https=) |
| NZ (1) | NZ600355A (https=) |
| PE (2) | PE20130309A1 (https=) |
| PL (2) | PL2465492T3 (https=) |
| PT (2) | PT2465492E (https=) |
| RU (1) | RU2010118457A (https=) |
| SG (2) | SG187458A1 (https=) |
| SI (2) | SI2952177T1 (https=) |
| TN (1) | TN2010000136A1 (https=) |
| TW (1) | TW200927142A (https=) |
| WO (1) | WO2009048993A2 (https=) |
| ZA (1) | ZA201001819B (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2278960T5 (pl) | 2008-03-17 | 2020-06-29 | Actelion Pharmaceuticals Ltd. | Schemat dawkowania dla selektywnego agonisty receptora sip1 |
| KR101618906B1 (ko) * | 2008-08-18 | 2016-05-09 | 노파르티스 아게 | 말초 신경병증의 치료를 위한 화합물 |
| JP5657565B2 (ja) * | 2008-12-22 | 2015-01-21 | ノバルティス アーゲー | Ｓ１ｐ受容体アゴニストの投与レジメン |
| TW201028143A (en) * | 2008-12-22 | 2010-08-01 | Novartis Ag | Dosage regimen for a S1P receptor agonist |
| EP2560618A1 (en) * | 2010-04-22 | 2013-02-27 | Ratiopharm GmbH | Melt-granulated fingolimod |
| EA201291096A1 (ru) * | 2010-04-22 | 2013-04-30 | Рациофарм Гмбх | Финголимод в форме твердого раствора |
| CN101973898B (zh) * | 2010-09-09 | 2013-06-19 | 南京明生医药技术有限公司 | 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用 |
| JP6111202B2 (ja) * | 2011-01-07 | 2017-04-05 | ノバルティス アーゲー | 免疫抑制製剤 |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| ES2388273B1 (es) * | 2011-03-16 | 2013-10-01 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| US9186333B2 (en) * | 2011-08-01 | 2015-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions of fingolimod |
| BR112014009141A8 (pt) * | 2011-10-21 | 2017-06-20 | Novartis Ag | regime de dosagem para um modulador ou agonista do receptor s1p |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| JP2014129238A (ja) * | 2012-12-28 | 2014-07-10 | Lion Corp | エトドラク含有固形製剤 |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| EP2996681B1 (en) * | 2013-05-13 | 2019-12-18 | Synthon B.V. | Pharmaceutical composition comprising fingolimod |
| EP3027174B1 (en) | 2013-07-29 | 2019-07-24 | Aizant Drug Research Solutions Private Limited | Pharmaceutical compositions of fingolimod |
| US20150141520A1 (en) * | 2013-11-18 | 2015-05-21 | Chandrasekhar Kandi | Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof |
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| ES2865451T3 (es) * | 2014-04-10 | 2021-10-15 | Novartis Ag | Formulación inmunosupresora |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016026461A1 (en) * | 2014-08-22 | 2016-02-25 | Sunshine Lake Pharma Co., Ltd. | Solid composition of fingolimod and preparation thereof |
| WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| RU2017112748A (ru) * | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| JP6680297B2 (ja) * | 2015-04-28 | 2020-04-15 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| RU2639424C2 (ru) * | 2015-09-15 | 2017-12-21 | Закрытое Акционерное Общество "Биокад" | Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза |
| EP3355863A4 (en) * | 2015-10-02 | 2019-06-19 | Mylan, Inc | STABLE FORMULATIONS OF FINGOLIMOD |
| TWI833686B (zh) * | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| EP3419607B1 (en) | 2017-03-29 | 2019-11-20 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| JP7365409B2 (ja) | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US12116285B2 (en) | 2018-10-05 | 2024-10-15 | Fuji Chemical Industries Co., Ltd. | Porous silica particle composition |
| CN117202893A (zh) * | 2021-04-14 | 2023-12-08 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物 |
| CN117120038A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的固体制剂的制备方法 |
| US20240207242A1 (en) * | 2021-04-14 | 2024-06-27 | Lg Chem, Ltd. | Pharmaceutical composition comprising sphingosine-1-phosphate receptor agonist with controlled particle size |
| WO2024126409A1 (en) | 2022-12-12 | 2024-06-20 | Synthon B.V. | Pharmaceutical composition of siponimod |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69321823T2 (de) | 1992-10-21 | 1999-06-02 | Taito Co., Ltd., Tokio/Tokyo | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| EP0778263B1 (en) | 1994-08-22 | 2002-01-09 | Welfide Corporation | Benzene compound and medicinal use thereof |
| US5616621A (en) * | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
| WO1997024112A1 (en) | 1995-12-28 | 1997-07-10 | Yoshitomi Pharmaceutical Industries, Ltd. | External preparation |
| KR20000075745A (ko) | 1997-02-27 | 2000-12-26 | 가마후라 아키오 | 의약 조성물 |
| ES2240868T3 (es) | 1997-04-04 | 2005-10-16 | Mitsubishi Pharma Corporation | Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis. |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| CN1328387C (zh) | 2000-07-13 | 2007-07-25 | 三共株式会社 | 氨基醇衍生物 |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| CA2461212C (en) | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| DE60235900D1 (de) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| JP4430941B2 (ja) | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬 |
| JP4571497B2 (ja) | 2002-09-19 | 2010-10-27 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| BRPI0407658A (pt) | 2003-02-18 | 2006-02-21 | Kyorin Seiyaku Kk | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico |
| PE20130200A1 (es) * | 2003-04-08 | 2013-03-09 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| TW200503783A (en) | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| FR2854549B1 (fr) | 2003-05-06 | 2005-06-24 | Actis Ets | Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| PL1643983T3 (pl) | 2003-06-24 | 2010-10-29 | Univ Connecticut | Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy |
| ATE449069T1 (de) | 2003-08-28 | 2009-12-15 | Novartis Pharma Gmbh | Aminopropanolderivate |
| AU2004271804B2 (en) * | 2003-09-12 | 2011-01-06 | Newron Sweden Ab | Treatment of disorders of the nervous system |
| UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
| WO2005113330A1 (en) | 2004-05-05 | 2005-12-01 | Adler, Richard, S. | Systems and methods for protecting ship from attack on the surface or under water |
| GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| US8633161B2 (en) | 2005-03-24 | 2014-01-21 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of leukemia |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| HUE046441T2 (hu) * | 2006-09-26 | 2020-02-28 | Novartis Ag | S1P modulátort tartalmazó gyógyászati készítmények |
-
2008
- 2008-10-09 EP EP20176933.8A patent/EP3733161A1/en not_active Withdrawn
- 2008-10-09 EP EP15173766.5A patent/EP2952177B1/en active Active
- 2008-10-09 AU AU2008310846A patent/AU2008310846C1/en active Active
- 2008-10-09 EP EP13177175.0A patent/EP2653154A1/en not_active Withdrawn
- 2008-10-09 CA CA2699788A patent/CA2699788C/en active Active
- 2008-10-09 HU HUE12155251A patent/HUE027696T2/en unknown
- 2008-10-09 CA CA2925175A patent/CA2925175A1/en not_active Abandoned
- 2008-10-09 WO PCT/US2008/079264 patent/WO2009048993A2/en not_active Ceased
- 2008-10-09 HU HUE15173766A patent/HUE053835T2/hu unknown
- 2008-10-09 ES ES12155251.7T patent/ES2545361T3/es active Active
- 2008-10-09 PL PL12155251T patent/PL2465492T3/pl unknown
- 2008-10-09 AR ARP080104420A patent/AR068986A1/es not_active Application Discontinuation
- 2008-10-09 EP EP16182588.0A patent/EP3120833A1/en not_active Withdrawn
- 2008-10-09 BR BRPI0818161A patent/BRPI0818161B8/pt active IP Right Grant
- 2008-10-09 DK DK15173766.5T patent/DK2952177T3/da active
- 2008-10-09 MY MYPI2010001202A patent/MY159358A/en unknown
- 2008-10-09 CN CN200880111160A patent/CN101820916A/zh active Pending
- 2008-10-09 SI SI200832164T patent/SI2952177T1/sl unknown
- 2008-10-09 PL PL15173766T patent/PL2952177T3/pl unknown
- 2008-10-09 NZ NZ600355A patent/NZ600355A/xx not_active IP Right Cessation
- 2008-10-09 SG SG2013002415A patent/SG187458A1/en unknown
- 2008-10-09 KR KR1020177004540A patent/KR20170021904A/ko not_active Withdrawn
- 2008-10-09 US US12/682,343 patent/US8673918B2/en not_active Expired - Fee Related
- 2008-10-09 EP EP20176935.3A patent/EP3733162A1/en not_active Withdrawn
- 2008-10-09 SI SI200831476T patent/SI2465492T1/sl unknown
- 2008-10-09 RU RU2010118457/15A patent/RU2010118457A/ru unknown
- 2008-10-09 EP EP12155251.7A patent/EP2465492B1/en not_active Revoked
- 2008-10-09 MX MX2010003925A patent/MX337152B/es active IP Right Grant
- 2008-10-09 JP JP2010529013A patent/JP6034000B2/ja active Active
- 2008-10-09 PT PT121552517T patent/PT2465492E/pt unknown
- 2008-10-09 PT PT151737665T patent/PT2952177T/pt unknown
- 2008-10-09 TW TW097139107A patent/TW200927142A/zh unknown
- 2008-10-09 JO JOP/2008/0436A patent/JOP20080436B1/ar active
- 2008-10-09 KR KR1020167004264A patent/KR101710845B1/ko active Active
- 2008-10-09 ES ES15173766T patent/ES2864671T3/es active Active
- 2008-10-09 KR KR1020107010336A patent/KR101600098B1/ko active Active
- 2008-10-09 SG SG10201800085XA patent/SG10201800085XA/en unknown
- 2008-10-09 EP EP08838495A patent/EP2209493A2/en not_active Withdrawn
- 2008-10-10 PE PE2012002520A patent/PE20130309A1/es not_active Application Discontinuation
- 2008-10-10 CL CL2008003003A patent/CL2008003003A1/es unknown
- 2008-10-10 PE PE2008001756A patent/PE20090799A1/es not_active Application Discontinuation
-
2010
- 2010-03-15 ZA ZA2010/01819A patent/ZA201001819B/en unknown
- 2010-03-15 IL IL204514A patent/IL204514B/en active IP Right Grant
- 2010-03-26 TN TNP2010000136A patent/TN2010000136A1/fr unknown
- 2010-04-28 CO CO10050315A patent/CO6270342A2/es not_active Application Discontinuation
- 2010-04-30 MA MA32805A patent/MA31799B1/fr unknown
- 2010-05-11 EC EC2010010169A patent/ECSP10010169A/es unknown
-
2014
- 2014-01-27 US US14/164,623 patent/US20140142192A1/en not_active Abandoned
- 2014-12-04 JP JP2014246066A patent/JP2015091822A/ja active Pending
-
2015
- 2015-02-25 US US14/631,102 patent/US9399066B2/en not_active Expired - Fee Related
- 2015-08-06 HR HRP20150838TT patent/HRP20150838T1/hr unknown
-
2016
- 2016-06-15 US US15/183,523 patent/US20160296481A1/en not_active Abandoned
-
2017
- 2017-02-14 US US15/432,628 patent/US20170151195A1/en not_active Abandoned
- 2017-09-08 US US15/698,742 patent/US20170368001A1/en not_active Abandoned
- 2017-11-19 IL IL255737A patent/IL255737B/en active IP Right Grant
-
2020
- 2020-10-13 IL IL277999A patent/IL277999A/en unknown
-
2021
- 2021-07-08 JO JOP/2021/0187A patent/JOP20210187A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500583A5 (https=) | ||
| JP2015091822A5 (https=) | ||
| NZ600355A (en) | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators | |
| EP1833467B1 (en) | Pharmaceutical compositions for sleep disorders | |
| CN110944638A (zh) | 尼拉帕尼组合物 | |
| KR100699958B1 (ko) | 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도 | |
| JP2008525313A (ja) | 抗痴呆薬の安定化方法 | |
| JP2014198723A (ja) | 口腔内分散性製剤 | |
| PT2200600E (pt) | Neramexano para utilização no tratamento de acufeno subagudo | |
| US20180028476A1 (en) | Stable dosage forms of levomilnacipran | |
| JP5941258B2 (ja) | 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール | |
| ES2700364T3 (es) | Comprimido de disgregación oral y método para su fabricación | |
| ES2668379T3 (es) | Método para el tratamiento de trastornos del movimiento con befiradol | |
| US20160008375A1 (en) | Pharmaceutical formulations comprising quetiapine and escitalopram | |
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 | |
| ES2814965T3 (es) | Composición farmacéutica que comprende un inhibidor de recaptación dual y método para la preparación de la misma | |
| CA2566331A1 (en) | Oral delivery system | |
| JP2017031117A (ja) | 光安定性を向上した、イミダフェナシン製剤 | |
| JP2023502738A5 (https=) | ||
| US20180147148A1 (en) | Pharmaceutical composition of teriflunomide | |
| EP2959889A1 (en) | Orally disintegrating formulations of loxoprofen | |
| JP2016537344A5 (https=) | ||
| WO2013100870A1 (en) | New antipsychotic compositions | |
| CA2790933A1 (en) | Stable dosage forms of levomilnacipran | |
| RU2021123106A (ru) | Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (s1p) |